Translation and Clinical Development of Bispecific T‐cell Engaging Antibodies for Cancer Treatment
Sign Up to like & getrecommendations! Published in 2017 at "Clinical Pharmacology and Therapeutics"
DOI: 10.1002/cpt.651
Abstract: Bispecific T‐cell Engagers (BiTE®) antibody constructs enable a polyclonal T‐cell response to cell‐surface tumor‐associated antigens, bypassing the narrow specificities of T‐cell receptors and the need for antigen presentation through the major histocompatibility complex pathways. Blinatumomab,… read more here.
Keywords: bite antibody; bispecific cell; pharmacology; cell ... See more keywords
Abstract 3632: BiTE® antibody constructs for the treatment of SCLC
Sign Up to like & getrecommendations! Published in 2017 at "Cancer Research"
DOI: 10.1158/1538-7445.am2017-3632
Abstract: Small cell lung cancer (SCLC) is a highly aggressive neuroendocrine tumor with a poor prognosis and limited therapeutic options. Most patients present with extensive stage disease, where recent advances in immunotherapies, including bi-specific T cell… read more here.
Keywords: bite antibody; sclc; antibody; antibody constructs ... See more keywords
Abstract 1561: Evaluation of mesothelin BiTE® antibody constructs in models of pancreatic ductal adenocarcinoma
Sign Up to like & getrecommendations! Published in 2019 at "Immunology"
DOI: 10.1158/1538-7445.am2019-1561
Abstract: Bispecific T cell engager (BiTE®) antibody constructs are designed to redirect T cells to induce lysis of tumor cells through simultaneous binding to CD3 on T cells and to a tumor associated antigen. BiTE® antibody… read more here.
Keywords: bite; hle bite; msln hle; bite antibody ... See more keywords